Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).


CSE:RVV - Post by User

Comment by 1ottrunneron Feb 23, 2022 9:14am
218 Views
Post# 34453213

RE:Stick with RVV >>> Bucillamine will be needed >>>

RE:Stick with RVV >>> Bucillamine will be needed >>>

Ok, let's not just throw BS at the fan hoping for spring water.

Will Bucillamine offer support for this indication, Covid-19?

It might, but it will have to complete it's trial. Here in the USA. Will it pass in Turkey, possibly. If it does MF will sell the rights, he has likely already promised a percentage of the pie. He will certainly have to if he expects to get a quick approval there.

I expect he will sell the rights, he could use fresh GCG money (I'll get back to this).

The trial could have completed in the US already but MF blew it, simply that.

"I always liked science" says MF.  I've always like vaginas, doesn't make me a gynocologist. It's too bad he didn't always like investors, he might have hired a better group of brains to surround himself with.

The excerpt above inflammatory heart disease, you've kindly highlighted what you would like everyone to read. I hope that people pay close attention to the other 5 symptoms of this indication for which Buc offers no potential relief. heart failure, dysrhythmia, heart attacks, strokes and clotting 

THERE, that is the problem!

The antivirals that have thus far been approved offer some remedy to the basic indication which prevents all 6 symptoms. Those drugs don't require Terminator1 to highlight anything in their sales flyer.

AND FINALLY, back to the GCG issue.  MF is sitting on less that 8 million pesos right now. Maybe 6 or less.

Guess what time it is folks, it's finance time! At current SP expect no less that 100 million shares dilution and as many warrants. If MF wants to run against a new IND he will need 20 million MINIMUM.
That will happen before end of Q3.

Take the SP wipe out somewhere between 25 and 50 % of its value and that is how many pennies you will have in your pocket if you are holding this at that time.

 


TheTerminator1 wrote:

People with Covid-19 may face long-term cardiovascular complications, study says


Excerpt:

Compared with those who were never infected, people who had a coronavirus infection were more likely to have symptoms including inflammatory heart disease, heart failure, dysrhythmia, heart attacks, strokes and clotting in the long term. People with prior Covid-19 infections were more than 60% more likely to develop any cardiac issue. Many of these conditions, such as pulmonary embolisms, are life-threatening.

https://edition.cnn.com/2022/02/22/health/covid-cardiovascular-complications/index.html


<< Previous
Bullboard Posts
Next >>